FDA advisory committee meeting not needed for Portola Pharmaceuticals' betrixaban NDA Feb. 9, 2017 No Comments
Promising MOD-5014 results in a phase I/IIa clinical trial in hemophilia patients Feb. 3, 2017 No Comments
Sustained factor IX activity seen with single infusion of SPK-9001 gene therapy Feb. 3, 2017 No Comments
Increased potency of CB-2679d may allow subcutaneous dosing for hemophilia B Feb. 3, 2017 No Comments
Biogen completes separation of global hemophilia business and launches Bioverativ Feb. 3, 2017 No Comments
RSS